Commercializing Innovations in Alzheimer’s Research through SBIR/STTR Funding

Add to iCal Calendar 0

Date/Time
Date(s) - 8 Jul 2020 until 8 Jul 2020
11:00 AM - 12:00 PM

Location
Webinar


The National Institute on Aging (NIA) Office of Small Business Research (OSBR) is offering opportunities for you to learn more about NIA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs and additional resources to commercialize your research. NIA staff and partners are eager to share guidance on drafting and submitting a competitive application.

Commercializing Innovations in Alzheimer’s Research through SBIR/STTR Funding
Wednesday, July 8, 2020 from 11 – 12 AZ MST (2 p.m. to 3 p.m. ET )
Featured Speaker: Stephanie Davis, Ph.D., NIA Office of Small Business Research, NIH
Partners: Rhode Island Bio

Register for the July 8 workshop

This webinar will feature:

  • An overview of the SBIR/STTR programs and benefits of funding
  • Priority research interests for NIA-funded small businesses
  • Upcoming funding opportunities and deadlines
  • Application resources and programs 
  • Opportunities to discuss your application with OSBR staff

This webinar will be of interest to all individuals interested in the SBIR/STTR program.

A second webinar on July 21 will be of most interest to those who have a Phase II grant or are in the Phase II stage of a Fast-Track.

Find out if your business is eligible to apply for NIA’s small business programs. For more information, review our overview and tips for applicants, fact sheet, and our FAQs.

Questions?
To discuss your project ideas and related questions, please email the NIA Office of Small Business Office at niasmallbusiness@mail.nih.gov and include an executive summary describing your project with any specific aims you intend to address within your application.

About NIA OSBR
The NIA Small Business Innovation Research (SBIR) and Small Business Technology Transfer Programs (STTR) offer non-dilutive, no-strings-attached funding up to $2.5 million (depending on funding opportunity) to commercialize products addressing aging and aging-related diseases and conditions, Alzheimer’s disease and related dementias, and the special challenges and needs of older Americans.